Physician profile
Bashar A Mubashir
NPI 1336135474
$583.34
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $283 · 2020: $54.07 · 2021: $247.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $195.99 | 2019-2020 | |
| Amgen INC. | $107.33 | 2019-2021 | |
| Lilly USA, LLC | $55.95 | 2019-2021 | |
| Glaxosmithkline, LLC. | $52.42 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $32.73 | 2020-2021 | |
| Regeneron Healthcare Solutions, INC. | $21.48 | 2021 | |
| Epizyme, INC. | $18.00 | 2021 | |
| Kite Pharma, INC. | $17.90 | 2021 | |
| Merck Sharp & Dohme LLC | $16.71 | 2021 | |
| Pharmacyclics LLC, An Abbvie Company | $15.36 | 2021 | |
| Incyte Corporation | $12.99 | 2021 | |
| Seagen INC. | $12.60 | 2021 | |
| Daiichi Sankyo INC. | $11.97 | 2021 | |
| Pfizer INC. | $11.91 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bashar Mubashir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.